title: Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
abstract: To evaluate the antiretroviral activity of delavirdine mesylate, a non-nucleoside reverse transcriptase inhibitor of HIV-1, we performed a phase II, randomized, double-blind, multicenter trial comparing the three-drug combination of delavirdine with zidovudine and didanosine to two-drug combinations of these drugs. Patients with CD4 cell counts between 100 and 500 cells/mm3 without prior or <6 months of monotherapy with zidovudine or didanosine were randomized to one of four arms and observed on a follow-up basis for 48 weeks. In total, 544 patients were evaluated. In those assigned to the three-drug regimen, mean short-term (weeks 4-12) and long-term (weeks 40-48) change in CD4 cells from baseline were 49.3+/-8.1 and 65.4+/-13.4 cells/mm3, respectively; mean short-term and long-term HIV-1 RNA changes from baseline were -1.13 log10+/-0.12 and -0.73+/-0.12 copies/ml, respectively. These responses in CD4 cell counts and HIV-1 RNA levels were better in comparisons with each of the two-drug arms at all study points; however, differences were not consistently significant. Gastrointestinal side effects were experienced by 33% of patients (178 of 544), and 30% (121 of 407) receiving delavirdine experienced rash, only one case of which was severe. In this study, therapy with delavirdine + zidovudine + didanosine was safe and showed modest, but not always significant, antiviral activity and CD4 cell count benefit compared with two-drug regimens with these agents. Key
authors.affiliation: AIDS Program-Yale School of Medicine, Yale University, New Haven, Connecticut 06510-2483, USA.
authors.forename: G H
authors.initials: GH
authors.lastname: Friedland
authors.forename: R
authors.initials: R
authors.lastname: Pollard
authors.forename: B
authors.initials: B
authors.lastname: Griffith
authors.forename: M
authors.initials: M
authors.lastname: Hughes
authors.forename: G
authors.initials: G
authors.lastname: Morse
authors.forename: R
authors.initials: R
authors.lastname: Bassett
authors.forename: W
authors.initials: W
authors.lastname: Freimuth
authors.forename: L
authors.initials: L
authors.lastname: Demeter
authors.forename: E
authors.initials: E
authors.lastname: Connick
authors.forename: T
authors.initials: T
authors.lastname: Nevin
authors.forename: M
authors.initials: M
authors.lastname: Hirsch
authors.forename: M
authors.initials: M
authors.lastname: Fischl
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D020008:Delavirdine / Q000008:administration & dosage* / Q000009:adverse effects; D016049:Didanosine / Q000008:administration & dosage*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D012449:Safety; D015215:Zidovudine / Q000008:administration & dosage*
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D020008:Delavirdine; D016049:Didanosine